Cheetah Net Supply Chain Bolsa (NASDAQ: CTNT)

Últimas noticias sobre Cheetah Net Supply Chain (NASDAQ:CTNT) Bolsa

Cheetah Net Supply Chain

Cheetah Net Supply Chain Service Inc is a one-stop services including Warehousing, Logistics, International trading & Supply Chain Finance, Etc. It operate in single segment Logistics and warehousing services which focuses on providing freight forwarding services for clients shipping goods from the U.S. to mainland China or Hong Kong. Its services include: (i) cargo storage, (ii) freight forwarding, (iii) U.S. customs clearance, and (iv) labor services and cargo loading and unloading.

WIIM

Chemed shares are trading lower after the company reported worse-than-expected Q2 EPS and sales and lowered FY25 EPS guidance.

Rosenblatt analyst Kevin Cassidy maintains Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Buy and raises the price target from $185 to $200.

News

Price Target

Analyst Ratings

Rosenblatt Maintains Buy on Seagate Tech Hldgs, Raises Price Target to $200

Seaport Global analyst Walt Liptak downgrades Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) from Buy to Neutral.

Downgrades

GTLS

Seaport Global Downgrades Chart Industries to Neutral

IONS

Ionis Pharmaceuticals shares are trading higher after the company raised FY25 sales guidance above estimates.

Morgan Stanley analyst Joseph Moore maintains Marvell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) with a Equal-Weight and raises the price target from $73 to $80.

MRVL

Morgan Stanley Maintains Equal-Weight on Marvell Tech, Raises Price Target to $80

Avis Budget shares are trading lower following worse-than-expected Q2 EPS and sales.

PTON

Peloton shares are trading higher after UBS upgraded the stock from Neutral to Buy and raised its price target from $7.50 to $11.

Barrington Research analyst Alexander Paris maintains Carriage Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSV#NYSE">CSV</a>) with a Outperform and maintains $50 price target.

Barrington Research Maintains Outperform on Carriage Servs, Maintains $50 Price Target

WING

Wingstop shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

Morgan Stanley analyst Joseph Moore maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Overweight and raises the price target from $99 to $125.

ALAB

Morgan Stanley Maintains Overweight on Astera Labs, Raises Price Target to $125

Barrington Research analyst Alexander Paris maintains Adtalem Glb Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATGE#NYSE">ATGE</a>) with a Outperform and maintains $140 price target.

Adtalem Global Education Inc. Common Stock

ATGE

Barrington Research Maintains Outperform on Adtalem Glb Education, Maintains $140 Price Target

Morgan Stanley analyst Joseph Moore maintains Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) with a Overweight and raises the price target from $270 to $338.

AVGO

Morgan Stanley Maintains Overweight on Broadcom, Raises Price Target to $338

Managing in-house payroll processing and tax compliance can be a time-consuming challenge for small businesses. According to the National Small Business Association's <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nsbaadvocate.org%2Fpost%2Fpress-nsba-2024-survey-on-taxation-and-small-business%23%3A%7E%3Atext%3DThe%2520majority%2520of%2520small%252Dbusiness%2520owners%2520spend%2520more%2Ctheir%2520businesses%252C%2520one%252Din%252Dthree%2520cite%2520a%2520significant%2520impact.&amp;esheet=54298807&amp;newsitemid=20250730917247&amp;lan=en-US&amp;anchor=2025+survey&amp;index=1&amp;md5=34b0b19d62e952f1f52e9bccd28aff51">2025 survey</a>, 50 percent of small businesses spend more than three hours per month administering payroll taxes. To mitigate concerns around time and accuracy, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thryv.com%2F&amp;esheet=54298807&amp;newsitemid=20250730917247&amp;lan=en-US&amp;anchor=Thryv%26%23174%3B&amp;index=2&amp;md5=95638330058c719cecc66074466e11fd">Thryv&#xAE;</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>), the leading small business marketing and sales platform, has launched <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.thryv.com%2Fworkforce-center%2F&amp;esheet=54298807&amp;newsitemid=20250730917247&amp;lan=en-US&amp;anchor=Thryv+Workforce+Center&amp;index=3&amp;md5=27f52ab4af365a1cfe7321e2fa4132fd">Thryv Workforce Center</a>&#x2122;, a payroll solution designed for growing businesses. Powered by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fgusto.com%2F&amp;esheet=54298807&amp;newsitemid=20250730917247&amp;lan=en-US&amp;anchor=Gusto&amp;index=4&amp;md5=f27d0912867d5315c1a21794bd5ecb60">Gusto</a>&#x2122;, the leading people management platform for small businesses, Thryv Workforce Center saves SMBs valuable time by managing payroll and automated tax calculations directly within their existing Thryv account.
&nbsp;
Thryv Workforce Center, powered by Gusto, streamlines payments, taxes, and compliance — all inside the Thryv platform.
This full-service solution does more than just calculate pay. It simplifies the entire payroll process, combining essential tools into one platform that manages a business' HR, taxes, and staff payments. It can also perform tasks like direct deposit and the creation of tax forms.

THRY

Thryv Launches Payroll Tool With Gusto to Help Small Businesses Save Time on Taxes and Paychecks

These two clearances mark an important step forward for Bioventus and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029. With TalisMann&#x2122; and StimTrial&#x2122; now FDA-cleared, Bioventus offers a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility. This development also reinforces the Company's commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs.
"The FDA clearance of both TalisMann&#x2122; and StimTrial&#x2122; represents a significant step forward in our PNS business, providing patients with innovative technologies. It also creates an exciting growth opportunity for our business", said Anthony Doyle, General Manager, Pain and Restorative Therapies of Bioventus.
Portfolio Highlights:
<ul>
<li>TalisMann&#x2122;: Combines our patented electric field conduction technology with an integrated pulse generator to potentially reach deeper, larger nerves. This combination is designed to provide long-term relief from chronic nerve pain for patients, potentially increasing the number of patients who respond to neuromodulation therapy. From a physician's perspective, the increase in power allows for easier lead placement and potentially broadens addressable nerves. &nbsp;</li>
<li>StimTrial&#x2122;: Bioventus' first trial lead provides physicians the ability to evaluate patient response to PNS therapy, which we expect will facilitate physician adoption and payer reimbursement where trial assessments are required.</li>
</ul>
Commercial Launch:
Bioventus expects to begin a limited commercial release of both TalisMann&#x2122; and StimTrial&#x2122; in select U.S. markets during this third quarter, with a broader rollout planned for early 2026.

Health Care

General

The FDA Grants 510(k) Clearances For Bioventus' Talismann And Stimtrial, Expanding The Company's Portfolio Of Peripheral Nerve Stimulation Solutions For Chronic Pain Management

Benchmark analyst Cody Acree maintains Qorvo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) with a Buy and raises the price target from $95 to $125.

QRVO

Benchmark Maintains Buy on Qorvo, Raises Price Target to $125

Morgan Stanley analyst Joseph Moore maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Overweight and raises the price target from $170 to $200.

NVDA

Morgan Stanley Maintains Overweight on NVIDIA, Raises Price Target to $200

Guidance

Thryv Holdings Raises FY2025 Sales Guidance from $770.50M-$785.00M to $783.00M-$790.00M vs $778.77M Est

Morgan Stanley analyst Joseph Moore maintains Advanced Micro Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) with a Equal-Weight and raises the price target from $121 to $185.

Morgan Stanley Maintains Equal-Weight on Advanced Micro Devices, Raises Price Target to $185

Fortive (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) raises FY2025 GAAP EPS guidance from $2.23-$2.43 to $2.50-$2.60 vs $2.01 analyst estimate..

Fortive Raises FY2025 GAAP EPS Guidance from $2.23-$2.43 to $2.50-$2.60 vs $2.01 Est

D. Boral Capital analyst Jason Kolbert maintains Hoth Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) with a Buy and maintains $5 price target.

Comments

Cheetah Net Supply Chain

Noticias

Últimas noticias sobre Cheetah Net Supply Chain (NASDAQ:CTNT) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL